The Switzerland-based firm, which is a clinical-stage
oncology-focussed biopharmaceutical company, has received approval for
its investigational new drug (IND) application from the US Food and
Drug Administration (FDA) to study its oral Dihydroorotate
dehydrogenase (DHOHD) inhibitor for SARS-CoV-2 infection, Rhizen
Pharmaceuticals S A said in a statement.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/rhizen-pharmaceuticals-gets-usfda-approval-for-phase-one-clinical-trials-for-covid-19-drug/articleshow/79527035.cms
No comments:
Post a Comment